Pharmaceutical & Medical Device Product Approval, Clinical Trials

The news today leads off with the announcement by New Jersey based firm Synergy Research of its Israel Clinical Trials services. Its goal: to help the pharmaceutical and medical device industry avoid costly delays in early clinical trial development programs, in highly regulated environments such as the US and European Union member countries.

The dramatic shifts in the last decade, from US to Europe, then back to US, alongside with shifts to less western style countries, is evidence of the increasingly regulated environment for early and first in man clinical trials.
These conditions drastically extend timelines, increase costs, reduce patent life, prolong development life cycles, all spelling out to lost revenues on R&D efforts.

Synergy Research has taken extensive strides towards tapping in to a western style healthcare environment, with a diverse population, well suited towards early and first in man clinical trials. Israel is a no-nonsense appropriately regulated environment, perfectly structured for the early R&D life of drugs and devices.

Synergy Research conducts clinical trials in Israel, under GCP & ICH conditions, under INDs & IDEs. American clinical & regulatory staff execute and manage all programs conducted in Israel. All leading to the best possible data, under the most demanding standards, well under the time and costs for comparable studies conducted in the US or Europe.